Rituximab (MabThera®) subcutaneous formulation is indicated in adults for Non-Hodgkin’s lymphoma (NHL):
MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
|26/05/2014||22/09/2014||Full Pharmacoeconomic Evaluation Not Recommended|